Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of KAL-002 for Prevention of Radiation Enteritis
ChiCTR2600125446Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KAL_002 in radiation enteritis (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Incidence of grade 2–4 radiation enteritis-related diarrhea at Day 49 and Safety outcomes at Day 49. Planned start May 2026; status: not yet recruiting.
02
Drugs
KAL_002
03
Conditions
radiation enteritis
Beyond the preview
Go deeper on ChiCTR2600125446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125446.